Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00442923
Status:
WITHDRAWN
Last Update Posted:
2019-01-31
First Post:
2007-03-02
Brief Title:
The Evaluation of Stimulant Withdrawal
Sponsor:
Aaron J Janowsky
Organization:
Oregon Health and Science University
Study Overview
Official Title:
Scientific Component IV Pharmacotherapy to Prevent Methamphetamine Relapse
Status:
WITHDRAWN
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
This study was withdrawn for lack of progress No subjects were recruited
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MARC
Brief Summary:
The purpose of this research study is to determine whether Carvedilol an FDA approved beta blocker when administered for an 8-week period to veterans currently undergoing treatment for methamphetamine dependence 1 improves their ability to stay in treatment longer 2eases the aversive symptoms that accompany stimulant withdrawal and 3 increases the time they remain abstinent from methamphetamine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1P50DA018165 | NIH | None | httpsreporternihgovquickSearch1P50DA018165 |